Zoetis Inc. (NYSE:ZTS) Shares Purchased by Integral Investment Advisors Inc.

Integral Investment Advisors Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 18.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,107 shares of the company’s stock after purchasing an additional 325 shares during the period. Integral Investment Advisors Inc.’s holdings in Zoetis were worth $372,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Zoetis by 1.0% during the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after purchasing an additional 414,605 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Capital World Investors grew its stake in shares of Zoetis by 0.6% during the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after purchasing an additional 57,798 shares in the last quarter. Norges Bank acquired a new position in Zoetis in the fourth quarter valued at $980,646,000. Finally, Bank of New York Mellon Corp boosted its stake in Zoetis by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after acquiring an additional 178,303 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Zoetis stock traded up $0.60 during midday trading on Friday, reaching $183.49. 2,328,501 shares of the stock traded hands, compared to its average volume of 2,678,988. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The firm has a fifty day moving average price of $179.58 and a two-hundred day moving average price of $174.69. The firm has a market cap of $83.73 billion, a price-to-earnings ratio of 35.35, a PEG ratio of 2.78 and a beta of 0.86. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the firm earned $1.41 EPS. Zoetis’s revenue was up 8.3% on a year-over-year basis. On average, equities research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

ZTS has been the subject of several analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $200.00 price target on shares of Zoetis in a report on Tuesday. The Goldman Sachs Group decreased their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. HSBC cut their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.